Peter Lynch fit · Growth at a reasonable price (GARP)
Is Krystal Biotech, Inc. Common Stock (KRYS) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
38/100
DNo encaja
4/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a KRYS
PEG ≤ 1.0
clave—
EPS CAGR ≥ 15%
clave0.0%
Revenue CAGR ≥ 10%
41.2%
Net margin > 0
53.3%
Cómo se valora KRYS en otras estrategias
Datos financieros en vivo
Cap. mercado
$8.38B
PER (TTM)
91.5x
ROIC (TTM)
6.43%
Margen bruto
93.89%
Preguntas frecuentes
What is KRYS's Peter Lynch fit score?
KRYS scores 38/100 on our Peter Lynch fit engine — grade D. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own KRYS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends KRYS.
How often is this score updated?
KRYS's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende KRYS personalmente.